Moreover, targeting ACSS2 using CRISPR-Cas9 guides or a small-molecule inhibitor not only hinders tumor cell metabolism but also induces an anticancer immune response, thereby enhancing the effectiveness of chemotherapy in preclinical breast cancer models (177). The gene discussed is ACSS2; the disease is neoplasm.